List of Figures
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs


List of Tables
Table 1: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Diagnostic Guidelines
Table 2: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Late Stage Products (Phase-III)
Table 18: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Mid Stage Products (Phase-II)
Table 19: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products